Mesa Laboratories MLAB Balance Sheet Statement
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| $26.93M-7.1% | $28.98M+41.9% | $20.42M-4.0% | $21.28M-22.1% | $27.32M0.0% | ||
| $44.1M+9.6% | $40.23M+0.4% | $40.09M+2.6% | $39.07M-6.9% | $41.97M0.0% | ||
| $26.37M-0.7% | $26.56M-4.3% | $27.74M-1.3% | $28.11M+10.8% | $25.37M0.0% | ||
| $8.87M-10.1% | $9.87M+7.5% | $9.18M-6.4% | $9.81M+22.1% | $8.03M0.0% | ||
| $106.27M+0.6% | $105.63M+8.4% | $97.43M-0.8% | $98.26M-4.3% | $102.69M0.0% | ||
| $30.61M-3.1% | $31.6M-0.7% | $31.84M+0.5% | $31.69M-2.0% | $32.33M0.0% | ||
| $186.86M-1.3% | $189.3M+0.4% | $188.49M+0.2% | $188.05M+3.5% | $181.76M0.0% | ||
| $83.35M-7.0% | $89.65M-3.9% | $93.27M-4.2% | $97.4M+0.5% | $96.88M-1.3% | ||
| $19.16M+11.4% | $17.2M-3.7% | $17.86M-5.4% | $18.87M+3.0% | $18.32M0.0% | ||
| $427.75M-1.6% | $434.85M+1.0% | $430.35M-1.2% | $435.74M+0.6% | $433.35M0.0% | ||
| $4.93M-6.2% | $5.25M+3.2% | $5.09M-18.8% | $6.27M+9.1% | $5.75M0.0% | ||
| $19.01M+36.9% | $13.88M+38.3% | $10.04M-3.7% | $10.43M-41.6% | $17.86M0.0% | ||
| $14.72M+1.1% | $14.56M+2.1% | $14.26M-5.4% | $15.08M+2.5% | $14.71M0.0% | ||
| $3.69M-5.2% | $3.89M+2.0% | $3.82M+1.7% | $3.75M+6.5% | $3.52M-0.3% | ||
| $0— | $0— | $0-100% | $97.43M— | —— | ||
| $61.9M+13.8% | $54.4M+12.6% | $48.3M-67.7% | $149.49M-8.8% | $163.96M0.0% | ||
| $61.36M-2.2% | $62.72M-2.2% | $64.16M-2.1% | $65.53M-2.0% | $66.9M0.0% | ||
| $13.66M+24.6% | $10.96M-6.8% | $11.76M-7.1% | $12.66M+1.5% | $12.47M0.0% | ||
| $241.5M-2.7% | $248.16M-1.5% | $251.88M-4.3% | $263.25M-3.8% | $273.52M0.0% | ||
| $375.35M+1.8% | $368.56M+0.9% | $365.17M+1.1% | $361.36M+0.8% | $358.54M0.0% | ||
| -$185.75M-2.8% | -$180.73M+1.5% | -$183.47M+0.9% | -$185.07M+2.0% | -$188.94M0.0% | ||
| -$3.36M-195% | -$1.14M+64.8% | -$3.23M+14.9% | -$3.8M+61.1% | -$9.78M0.0% | ||
| $186.25M-0.2% | $186.69M+4.6% | $178.47M+3.5% | $172.5M+7.9% | $159.83M+3.0% | ||
| $427.75M-1.6% | $434.85M+1.0% | $430.35M-1.2% | $435.74M+0.6% | $433.35M0.0% | ||
| $19.16M+11.4% | $17.2M-3.7% | $17.86M-5.4% | $18.87M+3.0% | $18.32M0.0% | ||
| $1.5M+1.8% | $1.47M+0.1% | $1.47M-0.1% | $1.47M+7.5% | $1.37M0.0% | ||
| $83.35M-7.0% | $89.65M-3.9% | $93.27M-4.2% | $97.4M+0.5% | $96.88M-1.3% | ||
| $19.16M+11.4% | $17.2M-3.7% | $17.86M-5.4% | $18.87M+3.0% | $18.32M0.0% | ||
| $19.16M+11.4% | $17.2M-3.7% | $17.86M-5.4% | $18.87M+3.0% | $18.32M0.0% | ||
| $19.01M+36.9% | $13.88M+38.3% | $10.04M-3.7% | $10.43M-41.6% | $17.86M0.0% | ||
| $17.62M+13.3% | $15.55M+9.3% | $14.22M-11.5% | $16.07M-34.7% | $24.6M0.0% | ||
| $17.62M+13.3% | $15.55M+9.3% | $14.22M-11.5% | $16.07M-34.7% | $24.6M0.0% | ||
| $0— | $0— | $0-100% | $97.43M— | —— | ||
| $19.01M+36.9% | $13.88M+38.3% | $10.04M-3.7% | $10.43M-41.6% | $17.86M0.0% | ||
| $5.63M+9.1% | $5.16M+10.0% | $4.69M+11.1% | $4.22M+12.5% | $3.75M0.0% | ||
| $84.5M-14.0% | $98.25M-7.3% | $106M+657% | $14M+40.0% | $10M0.0% | ||
| $78.71M+18.2% | $66.61M-2.0% | $67.98M-59.2% | $166.72M-0.6% | $167.72M0.0% | ||
| $375.35M+1.8% | $368.56M+0.9% | $365.17M+1.1% | $361.36M+0.8% | $358.54M0.0% | ||
| $20.09M-8.0% | $21.83M+0.8% | $21.66M+0.5% | $21.56M+6.8% | $20.18M0.0% | ||
| $84.5M-14.0% | $98.25M-7.3% | $106M+657% | $14M+40.0% | $10M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Mesa Laboratories's total assets?
- Mesa Laboratories (MLAB) holds $427.7M in total assets, down 1.3% year over year.
- How much debt does Mesa Laboratories have?
- Mesa Laboratories carries $78.7M in total debt against $186.2M of shareholders' equity, a debt-to-equity ratio of 0.42.
- How much cash does Mesa Laboratories have?
- Mesa Laboratories holds $26.9M in cash and equivalents.
- Can Mesa Laboratories cover its short-term obligations?
- Its current ratio is 1.72 — current assets exceed current liabilities.
- Where does Mesa Laboratories's balance sheet data come from?
- Every line is extracted from Mesa Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
